NeOnc Appoints Josh Neman as CCO to Bolster FDA Approval Path

NeOnc Technologies Holdings has appointed Josh Neman, PhD as its new Chief Clinical Officer. Neman brings experience in cancer neuroscience, translational research, and academic medicine from USC's Keck School of Medicine. The appointment is expected to accelerate four clinical trials, including lead asset NEO100, nearing Phase 2a completion ahead of schedule. Neman's expertise is expected to bolster the FDA approval path and explore AI and quantum computing to enhance drug delivery.

NeOnc Technologies Holdings, Inc. (NTHI), a clinical-stage biopharmaceutical company specializing in innovative treatments for central nervous system (CNS) cancers and disorders, has appointed Dr. Josh Neman as its new Chief Clinical Officer (CCO). Dr. Neman brings extensive experience in cancer neuroscience, translational research, and academic medicine, having served as Associate Professor of Neurological Surgery and Physiology & Neuroscience at USC's Keck School of Medicine and Scientific Director of the USC Brain Tumor Center [1].

Dr. Neman's appointment is expected to significantly accelerate the company's clinical development strategy, particularly the four clinical trials currently underway. Among these, the lead asset, NEO100, is nearing completion of its Phase 2a trial ahead of schedule. NEO100 is a purified form of preillyl acid that has shown promise in treating glioblastoma [2]. Dr. Neman's expertise in neurooncological sciences and brain tumor biology will be crucial in overseeing these trials and integrating AI and quantum computing into NeOnc's drug delivery platform, further strengthening the company's commitment to precision therapies and FDA approval [1].

In his role as CCO, Dr. Neman will lead NeOnc's clinical development strategy, including investigator-initiated trials and precision oncology partnerships. He will also play a key role in expanding the company's research collaborations with academic institutions, regulatory agencies, and patient advocacy groups. His appointment signals a major step forward in NeOnc's mission to transform the treatment landscape for patients with life-threatening CNS cancers [1].

NeOnc Technologies' lead programs—NEO100-01, NEO100-02, NEO100-03, and NEO212—utilize proprietary formulations to bypass the blood-brain barrier and target malignancies with precision. The company's IP portfolio includes 176 patents worldwide, reflecting a broad platform with strong commercialization potential [3].

References:
[1] https://www.nasdaq.com/press-release/neonc-technologies-holdings-inc-appoints-dr-josh-neman-chief-clinical-officer-advance
[2] https://finance.yahoo.com/quote/NTHI/
[3] https://www.stocktitan.net/news/NTHI/